AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell Event on Thursday, April 16, 2026 at 4:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell Event on Thursday, April 16, 2026 at 4:00 PM ET. CEO Thomas K. Equels will give a corporate overview and business outlook and take live questions from investors.
A live video webcast will be available on the company Events page and a replay will be posted two hours after the presentation and accessible for 90 days.
Details
News Market Reaction – AIM
On Apr 9, the day this news came out, AIM closed 6.24% below the previous close.
Data tracked by StockTitan Argus for the Apr 9 session.
Key Figures
- Event date
- April 16, 2026
- Scheduled date of Virtual Investor Closing Bell Event
- Event time
- 4:00 PM ET
- Start time of live webcast with CEO
- Replay availability delay
- 2 hours
- Replay becomes available two hours after live presentation
- Replay window
- 90 days
- Webcast replay accessible for 90 days on company website
Historical Context
-
Final approval of Japanese cancer therapy patent covering Ampligen combinations.
-
Closing of rights offering generating about $1.8M total subscriptions.
-
Preliminary rights offering results for estimated $1.8M gross proceeds.
-
Agreement to design Phase 3 Ampligen trial after positive Phase 2 DURIPANC signals.
-
Updated terms and reminder of March 3 expiration for rights offering.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET
Register for the event here
OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event on Thursday, April 16, 2026, at 4:00 PM ET.
Mr. Equels will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.